Principal Financial Group, Inc. · PFG · FY2026 Q1 · Calendar Q2 2026
Principal Financial Posts 13% EPS Growth on Record Retirement Deposits and Specialty Benefits
Principal Financial Group opened fiscal 2026 with 13% adjusted EPS growth to $2.07, beating the $2.01 consensus by roughly 3%. The quarter showed broad-based momentum: retirement transfer deposits grew 35% year-over-year, specialty benefits sales set a record with 24% growth, and Investment Management gross sales reached $37 billion. Management maintained the full-year 2026 outlook of 9-12% EPS growth and 15-17% ROE first introduced last quarter, indicating Q1 results track within but not ahead of the target range. The market response was measured — a 1.6% abnormal move followed by a 4.5% subsequent drift higher. Revenue of $3.52 billion fell short of the $4.12 billion estimate; the provided transcript analysis does not attribute the gap to a specific cause. The stock currently trades at $113.95, above the analyst consensus target of $104.67, suggesting the market is pricing in…
Company context
Snapshot as of publicationPrincipal Financial Group, Inc. engages in the investment management offering business. It offers financial products and services to businesses, individuals, and institutional clients. It operates its business through the following segments: Retirement and Income Solutions, Principal Asset Management, and Benefits and Protection. The Retirement and Income Solutions Segment offers a comprehensive portfolio of products and services for retirement savings along with select products for retirement income. The Principal Asset Management segment provides global investment solutions to institutional, retirement, retail and high net worth investors in the U.S. and select emerging markets. The Benefits and Protection segment includes selling individual life insurance products. The company was founded by Edward A. Temple in 1879 and is headquartered in Des Moines, IA.
Earnings scorecard
Reported versus consensusEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | In Line | In Line | Maintain | Jul 28, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Jul 28, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 22, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 21, 2026 |
| Keefe, Bruyette & Woods | Market Perform | Market Perform | Maintain | Jul 13, 2026 |
| Jefferies | Hold | Hold | Maintain | Jul 10, 2026 |
| Barclays | Underweight | Underweight | Maintain | Jul 7, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 6, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jun 24, 2026 |
| Raymond James | Outperform | Strong Buy | Downgrade | May 19, 2026 |
| UBS | Neutral | Neutral | Maintain | Apr 9, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Jan 21, 2025 |
| Citigroup | Sell | Sell | Maintain | Jul 23, 2024 |
| Goldman Sachs | Sell | Sell | Maintain | Jan 9, 2023 |
| Credit Suisse | Underperform | Neutral | Downgrade | Dec 8, 2022 |
| Wolfe Research | Perform | Peer Perform | Maintain | Jan 21, 2022 |
| Deutsche Bank | Hold | Hold | Maintain | Aug 3, 2016 |
| Bank of America | Neutral | Buy | Downgrade | Jun 29, 2016 |
| Macquarie | Outperform | Outperform | Maintain | Dec 4, 2015 |
| Keefe Bruyette & Woods | Market Perform | Market Perform | Maintain | Oct 12, 2015 |
| Atlantic Equities | Overweight | Overweight | Maintain | Dec 3, 2014 |
| Sterne Agee | Neutral | Neutral | Maintain | Oct 13, 2014 |
| Sandler O'Neill | Buy | Hold | Upgrade | Apr 28, 2014 |
| Evercore Partners | Equal Weight | Underweight | Upgrade | Apr 11, 2014 |
| Scotiabank | Sector Underperform | Sector Perform | Downgrade | Nov 22, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $113.95. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Wells Fargo | Wes Carmichael | $113 | $109.57 | -0.8% | Jul 22, 2026 |
| Atlantic Equities | Analyst unavailable | $94 | $113.09 | -17.5% | Jul 15, 2026 |
| Jefferies | Analyst unavailable | $98 | $111.67 | -14.0% | Jul 10, 2026 |
| Barclays | Analyst unavailable | $92 | $112.55 | -19.3% | Jul 7, 2026 |
| Piper Sandler | John Barnidge | $125 | $112.36 | +9.7% | Jun 24, 2026 |
| Morgan Stanley | Analyst unavailable | $107 | $103.3 | -6.1% | May 21, 2026 |
| Raymond James | Wilma Burdis | $111 | $101.85 | -2.6% | May 19, 2026 |
| Evercore ISI | Analyst unavailable | $108 | $99.34 | -5.2% | Apr 27, 2026 |
| Barclays | Alex Scott | $87 | $97 | -23.7% | Apr 24, 2026 |
| UBS | Michael Ward | $94 | $92.32 | -17.5% | Apr 9, 2026 |
| Wells Fargo | Analyst unavailable | $85 | $90.2 | -25.4% | Jan 13, 2026 |
| UBS | Michael Ward | $92 | $92.36 | -19.3% | Jan 8, 2026 |
| Barclays | Analyst unavailable | $85 | $90.88 | -25.4% | Jan 8, 2026 |
| Piper Sandler | Analyst unavailable | $100 | $89.24 | -12.2% | Dec 23, 2025 |
| Morgan Stanley | Analyst unavailable | $93 | $90.5 | -18.4% | Dec 15, 2025 |
| Morgan Stanley | Bob Huang | $81 | $79.14 | -28.9% | Oct 23, 2025 |
| Evercore ISI | Analyst unavailable | $94 | $81.77 | -17.5% | Oct 9, 2025 |
| Barclays | Analyst unavailable | $83 | $83.57 | -27.2% | Oct 8, 2025 |
| Morgan Stanley | Analyst unavailable | $80 | $83.41 | -29.8% | Oct 7, 2025 |
| Piper Sandler | Analyst unavailable | $94 | $83.41 | -17.5% | Oct 7, 2025 |
| Morgan Stanley | Bob Huang | $77 | $77.65 | -32.4% | Aug 18, 2025 |
| Wells Fargo | Elyse Greenspan | $69 | $78.3 | -39.4% | Jan 14, 2025 |
| Bank of America Securities | Joshua Shanker | $91 | $87.51 | -20.1% | Oct 10, 2024 |
| Barclays | Alex Scott | $74 | $81.14 | -35.1% | Sep 4, 2024 |
| Morgan Stanley | Bob Huang | $83 | $77.67 | -27.2% | Aug 19, 2024 |
| RBC Capital | Mark Dwelle | $87 | $81.44 | -23.7% | Jul 29, 2024 |
| Jefferies | Suneet Kamath | $76 | $87.46 | -33.3% | Jul 18, 2024 |
| Jefferies | Suneet Kamath | $78 | $79.46 | -31.5% | Jun 28, 2024 |
| Piper Sandler | John Barnidge | $85 | $84.56 | -25.4% | May 17, 2024 |
| Piper Sandler | John Barnidge | $90 | $84.6 | -21.0% | Apr 5, 2024 |
| Morgan Stanley | Bob Huang | $75 | $78.69 | -34.2% | Feb 15, 2024 |
| Goldman Sachs | Alex Scott | $64 | $69.38 | -43.8% | Dec 2, 2021 |
| Credit Suisse | Andrew Kligerman | $82 | $61.5 | -28.0% | Jul 5, 2021 |
Track every rating change on PFG the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session closeFollow PFG with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Guidance sentiment shifted from raised to maintained. Last quarter, management introduced the 2026 outlook with 9-12% EPS growth and 15-17% ROE targets; this quarter they reaffirmed those targets without adjustment. Adjusted EPS growth held at 13% year-over-year, consistent with the upper end of the full-year range. Capital returns continued at $375 million in Q1, on pace toward the $1.5-1.8 billion annual deployment target. New developments include a small dental network acquisition in Alabama and discussion of DOL safe-harbor guidance for private-market assets in retirement plans. The prior quarter's notable items — the Chile runoff annuities divestiture and the Saudi Arabia Islamic bank partnership — were not revisited as new announcements.
Guidance delta
Last quarter, management raised guidance and introduced the 2026 outlook targeting 9-12% EPS growth, 15-17% ROE, higher margin goals, and $1.5-1.8 billion in capital deployment. This quarter, guidance was maintained — management reaffirmed confidence in meeting those targets without upward revision. Q1 adjusted EPS growth of 13% sits at the upper end of the full-year range, though management did not signal that first-quarter strength alters the full-year trajectory.
Key takeaways
- Adjusted EPS grew 13% year-over-year, exceeding the upper end of the full-year target range.
- Retirement ecosystem transfer deposits grew 35% year-over-year, driven by participant roll-ins and higher deferrals.
- Specialty Benefits achieved record sales with a 24% year-over-year increase and improved loss ratios.
- Investment Management delivered record $37 billion in gross sales, up 21% year-over-year, with private-market net inflows of $400 million in the quarter.
- Capital position remains strong with $1.4 billion in excess capital; the company returned $375 million to shareholders and raised its dividend for the 12th consecutive quarter.
Management priorities
- Continue AI-driven technology enhancements across the organization.
- Launch new private-market strategies and expand the active ETF product line.
- Pursue strategic acquisitions, starting with the dental network in Alabama.
- Grow global distribution relationships, with focus on Asia and Brazil.
- Maintain disciplined capital allocation across share repurchases, dividend growth, and targeted capex.
Related earnings events
Financial ServicesSources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-30T21:12:33.307132+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T21:12:33.304367+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.